Jeet Mahal
Equibles does not estimate personal net worth.
Get an email with a short summary when Jasper Therapeutics, Inc. publishes a filing, an earnings call transcript or a press release.
Get JSPR alertsAbout Jeet Mahal
Jeet Mahal is recorded as COO, CEO and Board Member at Jasper Therapeutics, Inc. (JSPR). The newest filing on record that lists Jeet Mahal as CEO and Board Member at Jasper Therapeutics, Inc. (JSPR) is dated June 15, 2026. The newest filing on record that lists Jeet Mahal as COO at Jasper Therapeutics, Inc. (JSPR) is dated May 19, 2025. Jasper Therapeutics, Inc. reported in an 8-K filed September 28, 2026 that Jeet Mahal was appointed interim Principal Financial Officer, effective October 9, 2026. Jasper Therapeutics, Inc. reported in an 8-K filed January 7, 2026 that Jeet Mahal was appointed Chief Executive Officer and President, effective January 5, 2026. Jasper Therapeutics, Inc. reported in an 8-K filed January 7, 2026 that Jeet Mahal was appointed Class III director, effective January 5, 2026. The proxy statement of Jasper Therapeutics, Inc. reports total compensation of $1,289,599 for Jeet Mahal in fiscal 2025, including a base salary of $498,000. Disclosed compensation is on record for 6 fiscal years. Jasper Therapeutics, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Jasper Therapeutics, Inc. includes Ronald Martell (CEO and Board Member), William Lis (CEO), Howard Hoffen (Chairman) and 7 others.
“On September 28, 2026, the board of directors of the Company appointed Jeet Mahal, the Company’s President and Chief Executive Officer, as interim Principal Financial Officer, Rick Ruiz, the Company’s Vice President, Finance, as interim Principal Accounting Officer and Matthew Ros, the Company’s Chief Operating Officer, as the interim Corporate Secretary, each effective as of Mr. Cross’ resignation.”
“Effective January 5, 2026, the Board also appointed Jeet Mahal, the Company's current Chief Operating Officer, as the Company's Chief Executive Officer and President.”
Affiliation history
-
Current
Start not stated–present
Last confirmed May 19, 2025
-
Jasper Therapeutics, Inc. (JSPR)
Proxy statement
CurrentStart not stated–present
Last confirmed April 21, 2023
-
Current
Start not stated–present
Last confirmed June 15, 2026
-
Current
Start not stated–present
Last confirmed June 15, 2026
-
Start not stated–2022-04-29
Last confirmed by a filing; no departure on record
Company network
Leadership on record at Jasper Therapeutics, Inc.
- Ronald Martell CEO, Board Member
- William Lis CEO
- Howard Hoffen Chairman
- Thomas G. Wiggans Chairman, Board Member
- Matthew Ros COO, General Counsel
- Rick Ruiz Chief Accounting Officer
- Anna French, D. Phil. Board Member
- Christian W. Nolet Board Member
- Judith Shizuru, M.D., Ph.D. Board Member
- Kurt von Emster Board Member
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Jasper Therapeutics, Inc. (JSPR) | Chief Executive Officer and President; Former Chief Operating Officer | $498,000 | $1,289,599 |
| 2024 | Jasper Therapeutics, Inc. (JSPR) | Chief Executive Officer and President; Former Chief Operating Officer | $481,301 | $1,278,131 |
| 2023 | Jasper Therapeutics, Inc. (JSPR) | Chief Operating Officer | $461,693 | $1,184,707 |
| 2022 | Jasper Therapeutics, Inc. (JSPR) | Chief Operating Officer | $418,265 | $1,107,520 |
| 2021 | Jasper Therapeutics, Inc. (JSPR) | Chief Financial Officer, Chief Operating Officer and Corporate Secretary | $355,362 | $461,121 |
| 2020 | Jasper Therapeutics, Inc. (JSPR) | Chief Financial Officer, Chief Operating Officer and Corporate Secretary | $330,455 | $719,959 |